MSFT 415.85 -0.4643% AAPL 228.66 0.1665% NVDA 145.315 -1.153% GOOGL 175.65 -1.3867% GOOG 177.07 -1.3977% AMZN 202.88 -0.8455% META 564.135 0.5427% AVGO 162.61 -1.6571% TSLA 342.2799 -1.0752% TSM 186.825 -1.5% LLY 754.385 3.3786% V 307.39 -1.4302% JPM 240.935 -0.8865% UNH 601.41 4.2305% NVO 105.52 2.8159% WMT 87.12 0.6005% LVMUY 121.8 -0.5471% XOM 119.97 1.1296% LVMHF 607.0 -0.9465% MA 512.64 -1.3129%
Last update at 2024-11-19T20:00:00Z
| Breakdown | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
| Income before tax | -47.36800M | -45.85600M | -26.65800M | -22.87000M | -20.52600M |
| Minority interest | - | - | - | - | - |
| Net income | -40.48900M | -39.41000M | -22.05800M | -19.58200M | -18.41100M |
| Selling general administrative | 19.61M | 20.01M | 10.32M | 9.64M | 10.83M |
| Selling and marketing expenses | - | - | - | - | - |
| Gross profit | 6.62M | 4.96M | 1.72M | - | -9.74300M |
| Reconciled depreciation | 0.48M | 0.43M | 0.50M | 0.48M | 0.40M |
| Ebit | -48.59300M | -45.81400M | -30.98300M | -22.73400M | -20.57100M |
| Ebitda | -46.83900M | -45.42100M | -35.52900M | -22.35500M | -20.17200M |
| Depreciation and amortization | - | - | - | - | - |
| Non operating income net other | - | - | - | - | - |
| Operating income | -48.59300M | -45.81400M | -28.38600M | -22.73400M | -20.57100M |
| Other operating expenses | - | - | 1.49M | 1.49M | 1.49M |
| Interest expense | 0.05M | 0.00800M | 0.02M | 0.03M | 0.00000M |
| Tax provision | -6.87900M | -6.44600M | -4.60000M | -3.28800M | -2.11500M |
| Interest income | 0.23M | 0.01000M | 1.73M | 0.03M | 0.04M |
| Net interest income | 0.18M | 0.00200M | 1.73M | -0.00600M | 0.04M |
| Extraordinary items | - | - | - | - | - |
| Non recurring | - | - | - | - | - |
| Other items | - | - | - | - | - |
| Income tax expense | -6.87900M | -6.44600M | -3.49400M | -3.28800M | -2.11500M |
| Total revenue | 17.50M | 12.41M | 2.29M | 0.24M | 0.00000M |
| Total operating expenses | 66.09M | 58.23M | 30.68M | 22.98M | 20.57M |
| Cost of revenue | 10.88M | 7.46M | 3.76M | - | 9.74M |
| Total other income expense net | 1.05M | -0.04400M | -3.67900M | -0.13000M | 0.04M |
| Discontinued operations | - | - | - | - | - |
| Net income from continuing ops | -40.48900M | -39.41000M | -22.05800M | -19.58200M | -18.41100M |
| Net income applicable to common shares | -40.48900M | -39.41000M | -32.54700M | -19.58200M | -18.41100M |
| Preferred stock and other adjustments | - | - | - | - | - |
| Breakdown | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
| Total assets | 107.50M | 96.19M | 85.97M | 46.08M | 38.88M |
| Intangible assets | 0.32M | 0.02M | 0.02M | 0.03M | 0.06M |
| Earning assets | - | - | - | - | - |
| Other current assets | - | - | 1.49M | 0.89M | 0.88M |
| Total liab | 85.43M | 87.67M | 76.91M | 25.17M | 3.83M |
| Total stockholder equity | 22.07M | 8.53M | 9.06M | 20.91M | 35.05M |
| Deferred long term liab | - | - | - | - | - |
| Other current liab | 9.45M | 4.43M | 17.04M | 2.48M | 0.03M |
| Common stock | 5.39M | 4.49M | 4.17M | 3.92M | 3.55M |
| Capital stock | 5.39M | 4.49M | 4.17M | 3.92M | 3.55M |
| Retained earnings | -263.26300M | -222.96600M | -184.21500M | -151.99900M | -133.77700M |
| Other liab | 63.48M | 72.50M | 51.34M | 15.52M | - |
| Good will | 8.01M | 7.59M | 8.12M | 7.69M | 8.13M |
| Other assets | - | - | - | - | - |
| Cash | 54.82M | 73.54M | 27.45M | 13.52M | 21.49M |
| Cash and equivalents | - | - | - | - | - |
| Total current liabilities | 21.94M | 15.17M | 25.57M | 9.65M | 3.83M |
| Current deferred revenue | - | - | - | - | - |
| Net debt | - | - | - | - | - |
| Short term debt | - | - | - | - | - |
| Short long term debt | - | - | - | - | - |
| Short long term debt total | - | - | - | - | - |
| Other stockholder equity | 53.27M | 42.67M | 35.38M | 30.84M | 32.04M |
| Property plant equipment | 2.20M | 1.94M | 1.13M | 0.61M | 0.92M |
| Total current assets | 96.69M | 86.33M | 76.40M | 37.47M | 29.50M |
| Long term investments | 0.28M | 0.30M | 0.30M | - | 0.28M |
| Net tangible assets | 13.74M | 0.91M | 0.92M | 13.18M | 26.86M |
| Short term investments | 16.33M | - | 10.00M | 20.00M | 5.04M |
| Net receivables | 17.34M | 8.49M | 33.52M | 3.52M | 2.45M |
| Long term debt | - | - | - | - | - |
| Inventory | - | - | - | - | - |
| Accounts payable | 3.19M | 4.07M | 2.29M | 1.79M | 1.15M |
| Total permanent equity | - | - | - | - | - |
| Noncontrolling interest in consolidated entity | - | - | - | - | - |
| Temporary equity redeemable noncontrolling interests | - | - | - | - | - |
| Accumulated other comprehensive income | - | - | - | - | - |
| Additional paid in capital | - | - | - | - | - |
| Common stock total equity | - | - | - | - | - |
| Preferred stock total equity | - | - | - | - | - |
| Retained earnings total equity | - | - | - | - | - |
| Treasury stock | - | - | - | - | - |
| Accumulated amortization | - | - | - | - | - |
| Non currrent assets other | - | - | - | 8.61M | 9.39M |
| Deferred long term asset charges | - | - | - | - | - |
| Non current assets total | 10.81M | 9.86M | 9.57M | 8.61M | 9.39M |
| Capital lease obligations | 0.45M | 0.14M | 0.34M | 0.29M | - |
| Long term debt total | - | - | - | - | - |
| Breakdown | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
| Investments | -16.12500M | 10.00M | 10.00M | -15.00000M | -4.68100M |
| Change to liabilities | -3.45400M | 10.77M | 51.69M | 21.05M | 1.15M |
| Total cashflows from investing activities | -16.54200M | 8.68M | 9.62M | -15.01500M | -4.83000M |
| Net borrowings | -0.19000M | -0.21100M | -0.40200M | -0.40200M | -0.40200M |
| Total cash from financing activities | 43.05M | 30.71M | 15.43M | 5.27M | 0.34M |
| Change to operating activities | -4.22500M | 0.59M | -3.73100M | 0.04M | -0.92400M |
| Net income | -40.48900M | -39.41000M | -32.54700M | -19.58200M | -18.41100M |
| Change in cash | -18.72100M | 46.09M | 13.93M | -7.97900M | -21.25100M |
| Begin period cash flow | 73.54M | 20.64M | 27.03M | 21.49M | 42.74M |
| End period cash flow | 54.82M | 73.54M | 20.64M | 13.52M | 21.49M |
| Total cash from operating activities | -45.45600M | 6.81M | -10.77600M | 1.73M | -16.76000M |
| Issuance of capital stock | 43.24M | 30.92M | 15.83M | 5.27M | 0.34M |
| Depreciation | 0.48M | 0.43M | 0.50M | 0.48M | 0.40M |
| Other cashflows from investing activities | 0.02M | 0.01000M | 0.13M | -0.00600M | 0.04M |
| Dividends paid | - | - | - | - | - |
| Change to inventory | - | - | - | - | - |
| Change to account receivables | -0.58400M | 27.48M | -29.30200M | -0.00400M | 0.69M |
| Sale purchase of stock | - | - | - | - | 0.00000M |
| Other cashflows from financing activities | - | - | - | - | - |
| Change to netincome | 2.81M | 6.94M | 2.62M | -0.25800M | 0.34M |
| Capital expenditures | 0.14M | 1.31M | 0.51M | 0.00900M | 0.13M |
| Change receivables | - | - | - | - | - |
| Cash flows other operating | - | - | - | - | - |
| Exchange rate changes | - | - | - | - | - |
| Cash and cash equivalents changes | - | - | - | - | - |
| Change in working capital | -8.26300M | 38.84M | 18.66M | 21.09M | 0.91M |
| Stock based compensation | 10.25M | 8.63M | 4.39M | 0.58M | - |
| Other non cash items | -1.27200M | 0.04M | -4.67000M | 0.14M | -0.04500M |
| Free cash flow | -45.89600M | 5.47M | -11.29000M | 1.72M | -16.94800M |
Sector: Healthcare Industry: Biotechnology
| Company | Change (USD) | Price (USD) | Trailing PE (x) | Forward PE (x) | Price Sales TTM (x) | Price to Book Value (x) | Enterprise Value to Revenue (x) | Enterprise Value to EBITDA (x) |
|---|---|---|---|---|---|---|---|---|
| SLNCF Silence Therapeutics plc |
2.49 82.72% | 5.50 | - | - | 3.76 | 4.15 | 1.11 | -0.6246 |
| NVO Novo Nordisk A/S |
2.89 2.82% | 105.52 | 41.58 | 31.15 | 2.13 | 32.99 | 2.11 | 4.70 |
| NONOF Novo Nordisk A/S |
2.44 2.38% | 105.00 | 41.06 | 31.25 | 2.08 | 33.11 | 2.11 | 4.70 |
| VRTX Vertex Pharmaceuticals Inc |
0.44 0.10% | 448.45 | 29.67 | 24.33 | 10.38 | 5.83 | 9.33 | 20.00 |
| REGN Regeneron Pharmaceuticals Inc |
-1.25 0.17% | 743.35 | 29.07 | 20.12 | 7.57 | 3.82 | 6.95 | 19.42 |
Silence Therapeutics plc, a biotechnology company, focuses on the discovery and development of novel ribonucleic acid (RNA) therapeutics in hematology, cardiovascular, and other rare and metabolic indications. The company's mRNAi GOLD GalNAc Oligonucleotide Discovery platform that is used to target specific disease-associated genes in the liver. Its siRNA molecules to harness the body's natural mechanism of RNA interference, and degrading messenger RNA molecules that encode specific targeted disease-associated proteins in a cell. The company develops SLN360, which is in phase 2 clinical development to reduce high levels of lipoprotein; SLN124 that is in Phase I clinical trials for the treatment of non-transfusion dependent thalassemia, and Phase I clinical trials for the treatment of myelodysplastic syndrome; and polycythemia vera. It has collaboration agreements with AstraZeneca PLC to discover, develop, and commercialize small interfering siRNA therapeutics for the treatment of cardiovascular, renal, metabolic, and respiratory diseases; Hansoh Pharmaceutical Group Company Limited to develop siRNAs for three undisclosed targets leveraging Silence's mRNAi GOLD platform, as well as the company also collab with Mallinckrodt Pharma IP Trading DAC to develop and commercialize RNAi drug targets designed to silence the complement cascade in complement-mediated disorders. The company was formerly known as SR Pharma plc and changed its name to Silence Therapeutics plc in May 2007. Silence Therapeutics plc was incorporated in 1994 and is headquartered in London, the United Kingdom.
72 Hammersmith Road, London, United Kingdom, W14 8TH
| Name | Title | Year Born |
|---|---|---|
| Mr. Craig A. Tooman M.B.A., MBA | Pres, CEO & Exec. Director | 1966 |
| Ms. Rhonda L. Hellums | Chief Financial Officer | 1972 |
| Dr. Giles V. Campion M.D. | Exec. VP, Head of R&D, Chief Medical Officer and Exec. Director | 1954 |
| Ms. Gem Gokmen Hopkins | Head of IR & Corp. Communications | NA |
| Dr. John Strafford Ph.D. | Sr. VP of Bus. Devel., Alliance Management & New Product Devel. | NA |
| Mr. Jørgen Wittendorff | Sr. VP & Head of Manufacturing | NA |
| Dr. Barbara A. Ruskin J.D., Ph.D. | Sr. VP and Chief Intellectual Property & Innovation Officer | 1960 |
| Dr. Eric Floyd Ph.D. | Sr. VP of Regulatory Affairs & Quality Assurance | 1962 |
| Dr. Marie Wikstrom Lindholm Ph.D. | Sr. VP & Head of Molecular Design | NA |
Disclaimer - This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on ‘as is’ basis, using their API. The information and data provided on this page, as well as via the API, are not guaranteed to be real-time or accurate. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general informational purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine does not assume any responsibility for any trading losses you might incur as a result of using this information, data, or any analyst rating or recommendation provided. Kalkine will not accept any liability for any loss or damage resulting from reliance on the information, including but not limited to data, quotes, charts, analyst ratings, recommendations, and buy/sell signals sourced via the API.
Please be fully informed about the risks and costs associated with trading in the financial markets, as it is one of the riskiest forms of investment. Kalkine does not provide any warranties regarding the information on this page, including, without limitation, warranties of merchantability or fitness for a particular purpose or use.
US 
AU
UK
CA
NZ
Please wait processing your request...